Immunotherapy

Tissue TMB Superior to Blood TMB in Predicting Immunotherapy Response, Cleveland Clinic Study Finds

A recent Cleveland Clinic study confirms that tissue-derived tumor mutation burden (tTMB) is a more reliable predictor of immunotherapy response compared to blood-based TMB (bTMB). This finding serves as a cautionary note for physicians considering liquid biopsy results alone for treatment decisions.

Regeneron Immunotherapy Combo Fails in Melanoma Trial

Regeneron's recent melanoma trial results raise questions about the future of its immunotherapy combo. Analysts must assess the competitive landscape and investment implications.

Next-Generation Immunotherapy: Beyond PD-1/PD-L1 Inhibition in US Oncology

This article delves into next-generation immunotherapy strategies that extend beyond PD-1/PD-L1 inhibition, highlighting advancements in cancer treatment.

Greenwich LifeSciences GLSI-100 Abstract Accepted at ASCO 2026 for Breast Cancer Immunotherapy Trial

Greenwich LifeSciences announces ASCO 2026 abstract acceptance for GLSI-100, a Fast Track designated immunotherapy in Phase III trials for breast cancer recurrence prevention.

AACR 2026: ctDNA, Immunotherapy, and KRAS Target Breakthroughs

AACR 2026 in San Diego showcased transformative advances in precision oncology, including circulating tumor DNA surveillance for early-stage breast cancer, daraxonrasib achieving 58% response rates in KRAS-mutant pancreatic cancer, and next-generation CAR-T cells demonstrating deeper responses in multiple myeloma.

FDA Approves CancerVax for Adjuvant Melanoma Immunotherapy

The FDA has granted approval for CancerVax, a groundbreaking immunotherapy for adjuvant melanoma treatment, enhancing patient outcomes in skin cancer care.